{"abstract": "The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future.", "web_url": "https://dealbook.nytimes.com/2014/10/15/abbvies-u-turn-shows-shire-deal-was-driven-by-taxes/", "snippet": "The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future.", "lead_paragraph": "AbbVie\u2019s U-turn shows its Shire deal was mostly about tax breaks, after all.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg", "height": 360, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 360}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-jumbo.jpg", "height": 614, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-superJumbo.jpg", "height": 1200, "width": 2000, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "AbbVie\u2019s U-Turn Shows Shire Deal Was Driven by Taxes", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "AbbVie Inc", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Shire PLC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Treasury Department", "rank": 6, "major": "N"}], "pub_date": "2014-10-15T15:59:18+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Neil Unmack", "person": [{"firstname": "Neil", "middlename": null, "lastname": "Unmack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520", "word_count": 378, "uri": "nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520"}